Skip to main content

Table 1 Three clinical trials assessing a ketogenic diet as an adjuvant therapy for breast cancer

From: Does a ketogenic diet as an adjuvant therapy for drug treatment enhance chemotherapy sensitivity and reduce target lesions in patients with locally recurrent or metastatic Her-2-negative breast cancer? Study protocol for a randomized controlled trial

Identifiers and statusFirst postedDesignParticipantsInterventionsFollow-upPrimary outcomes
NCT03962647; not yet recruiting24 May 2019Single-group assignment, clinical trial30 patients, ER+ breast cancerExperimental: 2-week ketogenic dietAfter 2 weeks of a ketogenic dietPatients who complete the dietary intervention
NCT03535701; recruiting24 May 2018Non-randomized, clinical trial15 patients with stage IV breast cancer (KETO-CARE)Active comparator:aArm I (standard of care);
Experimental: arm II (standard of care, ketogenic diet)
Baseline up to 26 weeksAdherence and compliance to the ketogenic diet;
Changes in psychosocial measures;
Changes in physiological outcomes
NCT02092753; completed20 March 2014Non-randomized, clinical trial150 patients with breast cancer during the rehabilitation phasePlacebo comparator: standard diet;
Experimental: ketogenic diet;
Experimental: logi diet
20 weeks spanning 3 phases: 3 weeks of stationary intervention, 16 weeks of outhouse phase, and 1 final week of stationary interventionQuality of life. This will be assessed by comparing the results of the EORTC QLQ-30 and the QLQ-BR23 questionnaires